Source comparison
CJC-1295 Ipamorelin Protocol Anti-Aging: Secretagogue Stack Comparison
CJC-1295 + Ipamorelin GHRH analog (amplitude) + ghrelin mimetic (frequency) 100–300mcg ipamorelin + 100–500mcg CJC-1295 daily or split twice-daily 30–50% above baseline Minimal—ipamorelin is selective Gold standard for anti-aging—synergistic pulse restoration
This comparison does not assign a generated winner or score.
- CJC-1295 + Ipamorelin
- GHRH analog (amplitude) + ghrelin mimetic (frequency)
- 100–300mcg ipamorelin + 100–500mcg CJC-1295 daily or split twice-daily
- 30–50% above baseline
- Minimal—ipamorelin is selective
- Gold standard for anti-aging—synergistic pulse restoration without side-effect profile of older stacks
- Ipamorelin Solo
- Ghrelin receptor agonist (pulse frequency only)
- 200–300mcg 1–3× daily
- 15–25% above baseline
- Minimal
- Effective but leaves amplitude on the table—works well for recovery/sleep focus without body composition priority
- CJC-1295 Solo
- GHRH analog (pulse amplitude only)
- 500–1000mcg 1–2× weekly
- 20–35% above baseline
- Convenient (infrequent dosing) but less effective than dual-secretagogue approach—pulse frequency remains age-diminished
- Exogenous GH (pharma)
- Direct hormone replacement (somatropin)
- 2–4 IU daily subcutaneous
- 100–200% above baseline (dose-dependent)
- High—shutdown of endogenous production, insulin resistance risk
- Most powerful but riskiest—suppresses natural pulsatility, requires lifetime use, regulatory/cost barriers significant
- MK-677 (Ibutamoren)
- Oral ghrelin mimetic (non-peptide)
- 10–25mg oral daily
- 25–40% above baseline
- Moderate—appetite surge, possible insulin resistance
- Convenient (oral) but less selective than ipamorelin—chronic ghrelin elevation can impair glucose metabolism over time